Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Tumor Growth Delayed but Survival Not Proven: Why Did the FDA Not Approve the Ivonesimab Application?

Tumor Growth Delayed but Survival Not Proven: Why Did the FDA Not Approve the Ivonesimab Application?
In this article

Tumor Growth Delayed but Survival Not Proven: Why Did the FDA Not Approve the Ivonesimab Application?

The US Food and Drug Administration (FDA) has not approved the application for ivonesimab plus chemotherapy in advanced EGFR-mutant non-small cell lung cancer (NSCLC) after treatment with an EGFR-targeted drug. According to a statement by Summit Therapeutics on 15 November 2026, the FDA sent the company a “Complete Response Letter” (a formal reply saying the application cannot be approved in its current form). In the phase 3 HARMONi trial, the time before the tumor grew was longer, but the difference in overall survival did not reach statistical significance. According to the FDA, it was not shown that the drug’s benefit outweighs its risk. In this article I explain the reasoning behind the decision, the HARMONi data, the difference between PFS and overall survival, what the decision does and does not mean, and which options exist today for these patients. I covered the current picture in EGFR-mutant lung cancer in my 2026 article on EGFR-mutant lung cancer (in Turkish).

0.52hazard ratio for progression-free survival; median 6.8 vs 4.4 months
0.79hazard ratio for overall survival (p = 0.057); not significant in the prespecified analysis
16.8 / 14.0median overall survival, months (ivonesimab + chemotherapy / chemotherapy)
15 November2026: FDA’s Complete Response Letter announced
Quick Answer · Clinician Summary
  • What happened? The FDA declined to approve the application for ivonesimab plus platinum-containing chemotherapy in advanced non-squamous EGFR-mutant NSCLC that progressed after an EGFR-TKI, saying it “cannot be approved in its present form.” The action date for the application was 14 November 2026.
  • Rationale: In HARMONi, progression-free survival was significantly longer (HR 0.52; 6.8 vs 4.4 months), but overall survival, the co-primary endpoint, did not differ significantly (HR 0.79; p = 0.057). The FDA concluded that efficacy was not adequately shown without a meaningful survival gain.
  • What it does not mean: It does not mean ivonesimab has failed altogether. The drug is approved in China; first-line trials (HARMONi-3 and HARMONi-7) and studies in other cancers are ongoing.
  • Broader message: The FDA is increasingly cautious about approvals based on a PFS gain alone, particularly in advanced disease where effective treatments exist. A similar course unfolded in 2025 for patritumab deruxtecan.

Why does this topic matter?

EGFR-mutant lung cancer is a subtype seen particularly often in people who have never smoked and in patients of Asian descent. Most of these patients respond well for years to third-generation EGFR-targeted drugs such as osimertinib as first treatment. Eventually, however, the disease develops resistance to these drugs. Treatment options after this point are limited, and conventional immunotherapies have been largely ineffective in these patients (immunotherapy in lung cancer, osimertinib (Tagrisso), lung cancer guide, in Turkish).

As the first bispecific antibody to target PD-1 and VEGF at the same time, ivonesimab has been one of the most talked-about drugs of the past two years. Many large pharmaceutical companies have begun developing similar molecules. The FDA’s decision not to approve the first US application is therefore an important turning point, both for this drug class and for the question “is a PFS gain alone enough for approval?” (reading research news correctly, in Turkish).

A first? A short history of ivonesimab
May 2024
First approval in China
Ivonesimab, developed by Akeso, was approved for EGFR-mutant NSCLC after an EGFR-TKI based on the HARMONi-A trial conducted only in China. It became the first PD-1/VEGF bispecific antibody approved anywhere in the world.
2024-2025
Against pembrolizumab
In HARMONi-2, conducted in China, a PFS advantage over pembrolizumab was shown in first-line treatment of PD-L1-positive NSCLC; this result increased global interest in the drug (pembrolizumab, in Turkish).
2025
Global HARMONi results
PFS was significantly longer; the overall survival difference fell just outside the significance threshold (p = 0.057). In the same year, the FDA published draft guidance on assessing overall survival.
January 2026
FDA application
The FDA accepted the application for review; the action date was set for 14 November 2026.
15 November 2026
Complete Response Letter
The FDA concluded that, without a meaningful overall survival gain, the benefit-risk balance was not favorable.

What is ivonesimab?

Ivonesimab is a bispecific antibody that binds two different targets within a single molecule. One arm releases the PD-1 brake on the immune system; the other binds VEGF, which lets the tumor form new blood vessels. It therefore aims to combine immunotherapy and an anti-vessel treatment in one drug.

Combining immunotherapy drugs with anti-vessel drugs such as bevacizumab in lung cancer is not a new idea (bevacizumab, in Turkish). What sets ivonesimab apart is that it brings the two effects into one molecule and that its binding to PD-1 has been shown to become stronger around tumors rich in VEGF. Whether this theoretical advantage translates into real benefit for patients can only be answered by large clinical trials (bispecific antibodies, immunotherapy and its side effects, in Turkish).

Figure 1 · How does ivonesimab work?

Two targets, one molecule

Ivonesimab: bispecific antibodytwo separate binding arms in one molecule PD-1 armreleases the brakeon T cells;immunotherapy effect VEGF armblocks the tumor’snew-vessel signal;bevacizumab-like Joint binding around the tumorbinding to PD-1 grows stronger where VEGF is abundant Theoretical advantage, clinical proof neededthe key question: does it prolong survival?
How to read it: Ivonesimab carries two binding arms in a single antibody. The PD-1 arm releases the immune brake on T cells and produces an immunotherapy effect. The VEGF arm blocks the tumor’s signal to form new blood vessels. Binding to PD-1 has been shown to become stronger around tumors rich in VEGF. The real test of this theoretical advantage is whether it prolongs survival.

What did the HARMONi trial show?

HARMONi is a randomized, double-blind, placebo-controlled phase 3 trial that enrolled 438 patients from North America, Europe and Asia. All patients had advanced, non-squamous, EGFR-mutant NSCLC whose disease had progressed despite a third-generation EGFR-TKI (mostly osimertinib). About 38% of patients were from North America and Europe. One group received ivonesimab plus platinum-containing chemotherapy; the other received placebo plus the same chemotherapy. The trial had two co-primary endpoints: progression-free survival (PFS) and overall survival (OS).

At a median follow-up of 22 months, ivonesimab reduced the risk of disease progression by 48% (HR 0.52; 95% CI 0.41-0.66). Median PFS was 6.8 vs 4.4 months. Benefit was also evident in patients with brain metastases (HR 0.34). The tumor response rate was 44.7% vs 34.2%. However, in the prespecified primary analysis the difference in overall survival was not significant: HR 0.79 (95% CI 0.62-1.01; p = 0.057). Median overall survival was 16.8 vs 14.0 months. The results were presented in September 2025 at the World Conference on Lung Cancer (WCLC).

HARMONi: ivonesimab + chemotherapy vs placebo + chemotherapy

EGFR-mutant advanced NSCLC progressing after a third-generation EGFR-TKI; 438 patients; median time, months.

Progression-free survival · ivonesimab
6.8
Placebo
4.4
Overall survival · ivonesimab
16.8
Placebo
14.0

Progression-free survival: HR 0.52 (95% CI 0.41-0.66; p < 0.001). Overall survival: HR 0.79 (95% CI 0.62-1.01; p = 0.057); the median difference was 2.8 months but not statistically significant. Response rate 44.7% vs 34.2%.

In the following months the company released longer follow-up data. The hazard ratio fell to 0.78 in September 2025 (nominal p = 0.033) and to 0.76 in June 2026. No benefit had been seen in Western patients in the first analysis (HR 0.98); with longer follow-up the hazard ratio in this group also fell to 0.76. These updates are encouraging, but they have an important statistical limitation: in the trial plan the formal test is the primary analysis; later analyses cannot replace the primary analysis and increase the chance of a false-positive result.

Hazard ratio for overall survival over time

HARMONi, different data cut-off dates; 1 = no difference. Only the first row is the prespecified primary analysis.

April 2025 · primary analysis · all patients
0.79
April 2025 · Western patients
0.98
September 2025 · update · all patients
0.78
June 2026 · update · all patients
0.76
June 2026 · Western patients
0.76

The hazard ratio became smaller in later analyses (September 2025: 95% CI 0.62-0.98; nominal p = 0.033), but these are not formal tests under the prespecified statistical plan and have not undergone independent peer review. That no benefit was seen in Western patients in the first analysis raised the question of regional differences.

Safety in HARMONi

Ivonesimab + chemotherapy (colored) and placebo + chemotherapy (gray), %.

Grade 3 or higher treatment-related adverse events
50%
Placebo + chemotherapy
42.2%
Treatment discontinuation due to adverse events
7.3%
Placebo + chemotherapy
5%
Treatment-related loss of life
1.8%
Placebo + chemotherapy
2.3%

Most severe adverse events were changes in laboratory values. Adverse events related to vessel signaling, such as high blood pressure and protein in the urine, were more common in the ivonesimab arm. No new safety signal was reported.

Why did the FDA not approve it?

According to Summit’s statement, the FDA said the application “cannot be approved in its present form.” The reasoning is clear: without a statistically significant overall survival gain, evidence of efficacy was not considered adequate, and a PFS gain alone did not support a favorable benefit-risk balance. I see four points that likely contributed to this decision:

  • OS was a co-primary endpoint and was not met. The trial was designed for OS to be significant as well. The prespecified primary analysis did not reach this goal.
  • Regional difference. In the primary analysis the benefit came mainly from Asian patients; no OS difference was seen in Western patients. The FDA cares about applicability to patients in the US.
  • More adverse events. Severe adverse events were more common in the ivonesimab arm (50.0% vs 42.2%). This additional burden is harder to accept before a survival gain is proven.
  • The FDA’s growing emphasis on OS. In draft guidance published in August 2025, the FDA recommended careful examination of OS in all randomized cancer trials to assess possible harm, and prioritizing OS especially in later-line treatments.

Figure 2 · PFS or OS?

Two endpoints in HARMONi, two different results

PFS or OS?two endpoints, two different questions PFStime before thetumor grows; fastbut a surrogate OShow long thepatient lives; mostreliable, slow to read HARMONi: PFSHR 0.52; 6.8 vs4.4 monthssignificant HARMONi: OSHR 0.79; p = 0.057prespecified analysis:not significant FDA: in this application, PFS alone is not enoughan OS gain is needed to show the benefit-risk balance
How to read it: Progression-free survival (PFS) measures the time before the tumor grows; it gives results quickly but is a surrogate measure. Overall survival (OS) measures how long the patient lives; it is the most reliable endpoint but requires long follow-up. In HARMONi, PFS was significantly longer (HR 0.52); the OS difference was not significant in the prespecified analysis (HR 0.79; p = 0.057). The FDA looked for an OS gain in this application to demonstrate the benefit-risk balance.

A similar example: patritumab deruxtecan

A similar picture arose in 2025 in the same disease, in the period after an EGFR-TKI. The antibody-drug conjugate patritumab deruxtecan, which targets HER3, had significantly prolonged PFS compared with chemotherapy in the HERTHENA-Lung02 trial but could not show a significant difference in OS. After the companies met with the FDA in May 2025, they withdrew their application (antibody-drug conjugates, in Turkish). The ivonesimab decision is consistent with this line. Because this patient group has many treatment options after chemotherapy, it is especially important that a PFS gain translates into survival.

So what options exist for these patients today?

The options approved in the US for EGFR-mutant NSCLC progressing after osimertinib are as follows (FDA approvals in lung cancer in 2025, in Turkish):

Treatment Evidence Note
Platinum-containing chemotherapy (carboplatin-pemetrexed) Long-standing standard Backbone alone or of combinations
Amivantamab + carboplatin-pemetrexed MARIPOSA-2: PFS HR 0.48 FDA-approved (2024). OS data were not mature at the time of approval; in the second interim analysis HR was 0.73 and did not reach the prespecified significance threshold (amivantamab (Rybrevant), in Turkish)
Datopotamab deruxtecan Single-arm studies; response rate about 45% Accelerated FDA approval (2025) after EGFR-TKI and platinum-based chemotherapy (datopotamab deruxtecan, in Turkish)
Treatment by resistance mechanism MET amplification, histologic transformation, etc. Repeat biopsy or liquid biopsy with NGS is important at progression (What is NGS?, in Turkish)

A notable point here: the amivantamab combination was also approved on PFS data. The difference is this: when MARIPOSA-2 was approved, the OS analysis had not yet matured and there was no sign of harm; in HARMONi, by contrast, the prespecified primary OS analysis was complete and did not reach significance. In addition, the FDA’s approach to OS has tightened markedly since 2025. In China, new antibody-drug conjugates such as sacituzumab tirumotecan have reported survival gains in this patient group; I covered other data for this drug in lung cancer in my OptiTROP-Lung06 article (in Turkish).

What does this decision mean, and what does it not mean?

A “Complete Response Letter” is the formal reply in which the FDA states that it has not approved an application in its current form and what is missing. It is not a permanent ban; the company can reapply with additional data. This decision means that, for now, ivonesimab cannot be used in the US for EGFR-mutant lung cancer. It does not mean that the entire development program of the drug has failed.

  • Approvals continue in China: Ivonesimab has been approved in China for this indication since 2024 and for first-line treatment of PD-L1-positive NSCLC since 2025. In the final analysis of HARMONi-A, conducted only in China, a significant difference in overall survival was reported (HR 0.74; p = 0.019).
  • First-line trials: The global HARMONi-3 (with chemotherapy, squamous and non-squamous NSCLC) and HARMONi-7 (alone in PD-L1-high NSCLC; PD-L1 testing, in Turkish) trials are ongoing. The overall survival results of these trials will largely determine the drug’s future in the US.
  • Other cancers: Studies are ongoing in colorectal, bladder (with enfortumab vedotin), kidney, head and neck, and biliary tract cancers.
  • Drug class: Many companies are developing similar PD-1/VEGF bispecific antibodies. This decision showed once again how important overall survival is as a primary endpoint in trials of these drugs (WCLC 2026 summary, in Turkish).

Figure 3 · What does the FDA decision mean?

One application, one indication

What does the FDA decision mean?one application, one indication Meaningthis application cannotbe approved as is;no use in the US Not meaningdoes not mean thedrug has failedaltogether Chinaapprovals in 2024and 2025; HARMONi-AOS HR 0.74 Ongoing trialsHARMONi-3, -7;colorectal, bladder,kidney, head and neck More data and a new application possiblefirst-line results will be decisive
How to read it: The decision means that this application cannot be approved in its present form and that ivonesimab cannot, for now, be used in the US for EGFR-mutant lung cancer. It does not mean the drug has failed altogether. It was approved in China in 2024 and 2025; an OS HR of 0.74 was reported in HARMONi-A. HARMONi-3, HARMONi-7 and studies in other cancers are ongoing. A new application with additional data is possible; first-line results will be decisive.

The situation in Türkiye

As of November 2026, ivonesimab is not licensed in the US, Europe or our country. Access to this drug is currently possible only through clinical trials; because there is no US or European approval, importing the drug from abroad also appears practically impossible (cancer drugs imported from abroad, in Turkish). For our patients who progress after osimertinib, chemotherapy, the amivantamab combination and, where appropriate, treatments directed at the resistance mechanism are considered. For the licensing and reimbursement status of these drugs in our country, see my articles on lazertinib and the access map of FDA-approved drugs in Türkiye (in Turkish); for suitable clinical trials, see my article What is a clinical trial? (in Turkish).

Questions you can ask your doctor

  • Should a repeat biopsy or liquid biopsy be done to learn my resistance mechanism after progression on osimertinib?
  • Is chemotherapy, the amivantamab combination or another option more suitable for me?
  • Is the effect of these options on survival proven, or is there only PFS data?
  • Is there a clinical trial I could join?
  • How would my treatment plan change if I have brain metastases?
Common misconceptions
  • “The FDA banned ivonesimab.” No. It only declined to approve this application in its current form; a new application with additional data is possible.
  • “The drug doesn’t work.” It is not that clear-cut. It lengthened the time before the tumor grew; however, a survival benefit could not be proven in the global trial.
  • “If PFS is longer, survival must be longer too.” Not always. Later treatments, the biology of the disease and adverse events can prevent a PFS gain from translating into survival.
  • “p = 0.057 is almost significant, so there is a difference.” The statistical threshold is set in advance; a result that does not cross it does not prove that a real difference exists. But it does not prove that there is no difference either.
  • “The HR fell in later analyses, so the problem is solved.” Later analyses cannot replace the prespecified primary analysis; they are regarded as supporting information.

Frequently Asked Questions

Why did the FDA not approve ivonesimab?
The FDA did not approve the application for ivonesimab plus chemotherapy in advanced EGFR-mutant lung cancer because the HARMONi trial failed to show a statistically significant difference in overall survival. Progression-free survival was longer (HR 0.52), but the FDA did not find this alone sufficient for a favorable benefit-risk balance.
What is ivonesimab?
Ivonesimab is a bispecific antibody that simultaneously targets the PD-1 brake on the immune system and VEGF, the tumor’s blood-vessel growth signal. It is approved for lung cancer in China; as of November 2026 it is not licensed in the US, Europe or Türkiye.
What is the difference between PFS and overall survival?
Progression-free survival (PFS) measures the time before the disease progresses; overall survival (OS) measures the total time the patient lives. PFS gives results faster but does not always translate into survival. For this reason, the FDA places increasing weight on OS gain, especially in later-line treatments.
Which treatments exist for EGFR-mutant lung cancer that progresses after osimertinib?
Options include platinum-containing chemotherapy, amivantamab with chemotherapy, datopotamab deruxtecan in suitable patients, and targeted treatments directed at the resistance mechanism. The choice depends on repeat biopsy or liquid biopsy results and the patient’s condition.

Glossary

NSCLC
Non-small cell lung cancer; about 85% of lung cancers.
EGFR mutation
A gene change that keeps the tumor cell’s growth signal permanently on; it can be targeted with targeted drugs.
EGFR-TKI
Oral targeted drugs that suppress EGFR (for example, osimertinib).
Bispecific antibody
An antibody that can bind two different targets at the same time.
PD-1
A receptor on immune cells that the tumor uses to brake the immune system.
VEGF
The growth factor that lets the tumor form new blood vessels.
Progression-free survival (PFS)
The time during which the disease has not progressed and the patient has not experienced loss of life.
Overall survival (OS)
The total time the patient lives, counted from the start of treatment.
Complete Response Letter
The FDA’s formal reply stating that it has not approved an application in its current form and listing its deficiencies.
Prespecified analysis
The analysis defined in the statistical plan before the trial began, which formally evaluates the result.

DROZDOGAN Academy Commentary

This decision carries a message beyond a single drug: it is valuable for a new drug to control the tumor for longer, but unless it shows that patients live longer, it may not be enough for approval, especially in advanced disease where other options exist.

⚡ Why it matters

Ivonesimab is the first representative of the PD-1/VEGF bispecific antibody class. The FDA’s decision not to approve the first application will affect the design and expectations of all trials in this class.

✅ Strengths

HARMONi was double-blind and placebo-controlled; it showed a marked PFS benefit, consistent also in patients with brain metastases. With longer follow-up the OS hazard ratio decreased, and an OS gain was reported in HARMONi-A in China.

⚠️ Limits

The prespecified OS analysis is not significant; in the first analysis no OS benefit was seen in Western patients; severe adverse events are more frequent. Later analyses are supportive but not decisive.

🩺 In practice

In my patients who progress after osimertinib, I first perform a repeat biopsy or liquid biopsy to understand the resistance mechanism. I then consider chemotherapy, the amivantamab combination or suitable clinical trial options, discussing openly the level of evidence on survival.

❓ Open questions

Will HARMONi-3 and HARMONi-7 show an overall survival gain? Is the difference between Asian and Western patients real, or chance? Will other PD-1/VEGF bispecific antibodies give different results?

Conclusion: The FDA’s ivonesimab decision shows that it is this application, not the drug, that was found insufficient. In treatment after osimertinib in EGFR-mutant lung cancer, a survival gain remains the key criterion for approval.

Transparency note
  • This article was prepared in November 2026.
  • Information on the FDA decision is based on Summit Therapeutics’ statement of 15 November 2026; the FDA’s rejection letter is not publicly available.
  • HARMONi data are based on the WCLC 2025 presentation and the company’s later statements. The September 2025 and June 2026 updates are not prespecified primary analyses and have not undergone independent peer review.
  • Comparisons between different studies are indirect. The diagrams are simplified. The Academy commentary is my own.
  • This article is not medical advice; make decisions about your health together with your doctor.

Sources

  1. Summit Therapeutics. Summit Therapeutics provides update regarding ivonescimab Biologics License Application (15 November 2026). smmttx.com
  2. News-Medical. Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients (HARMONi, WCLC 2025). news-medical.net
  3. Targeted Oncology. Updated HARMONi analysis shows consistent OS benefit with ivonescimab in EGFR-mutant lung cancer (July 2026). targetedonc.com
  4. OncLive. FDA accepts BLA for ivonescimab plus chemotherapy in EGFR-mutant NSCLC after TKI progression (January 2026). onclive.com
  5. BioSpace. Ivonescimab HARMONi-A study final OS analysis results presented at SITC 2025 with OS HR 0.74. biospace.com
  6. U.S. Food and Drug Administration. Approaches to assessment of overall survival in oncology clinical trials. Draft guidance for industry, August 2025. fda.gov
  7. OncLive. BLA is withdrawn for patritumab deruxtecan in EGFR-mutated NSCLC (May 2025). onclive.com
  8. CancerNetwork. Amivantamab/chemo shows sustained OS in advanced EGFR NSCLC (MARIPOSA-2). cancernetwork.com
DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Tumor Growth Delayed but Survival Not Proven: Why Did the FDA Not Approve the Ivonesimab Application?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy